ASCO 2023: AstraZeneca’s PD-1/TIGIT shows promise in checkpoint-exposed NSCLC
Despite the significant improvement in overall survival in the NSCLC setting with the advent of ICIs, there is still a high level of unmet need.
ASCO 2023: Research backs chemo-only approach for some rectal cancer patients
Bellerophon’s study of fILD therapy fails to meet primary endpoint
Akero’s NASH candidate and Ozempic reduce liver fat in Phase IIb cohort
ASCO 2020: Janssen reports positive results for Talquetamab in Multiple myeloma
ASCO 2023: Janssen present positive follow-up data for first in line therapy for lung cancer
Analysis
View More
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Themes
View MoreCocrystal receives approval from HREC for Phase I trial of Covid-19 therapy
CDI-988 demonstrated in vitro potency against SARS-CoV-2 and other coronaviruses.
More themes
Insights
View MoreWho’s hiring who? Hiring activity related to social responsibility increased by 10% in the pharmaceutical industry in Q3 2022
The global pharmaceutical industry experienced a 10% rise in new job postings related to social responsibility in Q3 2022 compared…
Sinovac Biotech gets approval for clinical trial of Covid-19 injection
Role of machine learning tools in early diagnosis of Parkinson’s disease
Shionogi starts Phase I trial of Covid-19 antiviral in Japan
It’s a match! Connecting patients to clinical trials with AI